We previously demonstrated that high levels of PDE5 are immunodetected in quiescent, differentiated myometrial cells [2]; it will then be interesting to monitor PDE5 levels also in patients affected by uterine adenocarcinomas or leiomyomas. The gene discussed is PDE5A; the disease is leiomyoma.